FDA early alert: Intersurgical removes lots of 22mm Smoothbore breathing tubes and systems over connector disconnection and loss of ventilation risk
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · High priority
The Food and Drug Administration (FDA) posted an early alert on November 10, 2026 about Intersurgical Inc., which has told customers to remove listed lots of its 22mm Smoothbore breathing tubes and systems. Intersurgical sent the letter on November 3, 2026, telling customers to stop using and quarantine stock with the affected product and lot numbers and return it. Testing of internal stock found some products were made with too little solvent to secure the soft connectors to the tube. A connector that disconnects during use could cause loss of ventilation or compromised ventilation. As of November 3, 2026, the firm had reported no serious injuries or deaths.

Background
An FDA early alert notifies the public of a potentially high-risk device issue while FDA reviews it. Intersurgical 22mm Smoothbore breathing tubes and systems connect patients to machines that help them breathe; the firm acted after reports from markets outside the U.S. of soft connectors disconnecting from the tube.
Who this affects
Hospitals using Intersurgical 22mm Smoothbore breathing tubes and heated-wire, bilevel and exhalation-valve breathing systems (respiratory therapy, critical care, anesthesia, supply chain)
Why it matters
FDA and Intersurgical say to stop using and quarantine affected lots, which include heated-wire and bilevel breathing systems. Inference: respiratory therapy needs replacement circuits on hand. A disconnection during use could cause loss of or compromised ventilation, which may cause the patient to desaturate until ventilation is manually re-initiated.
Recommended action
- Check circuit stock against the reference and lot numbers on the FDA page and quarantine matches
- Return affected product to Intersurgical and share the notice with all users in the facility
- Confirm replacement circuits are available for ventilated and bilevel patients
- Report adverse events or quality problems to MedWatch
Implementation playbook
- Immediately check breathing tube and circuit stock in respiratory therapy, critical care and anesthesia against the reference and lot numbers on the FDA page, stop using any match, quarantine any stock with the affected product and lot numbers, and share the notice with every unit that sets up ventilator, bilevel or heated-wire breathing circuits. The Intersurgical letter, as FDA reports it, says to discontinue use and quarantine immediately. Owner: Respiratory therapy and Supply chain. Due: immediately.
- Return the quarantined lots to Intersurgical. Owner: Supply chain. Due: 2026-11-21.
- Confirm replacement circuits are stocked for ventilated and bilevel patients. Owner: Respiratory therapy. Due: 2026-11-18.
- Report any connector disconnection or loss of ventilation to MedWatch and to risk management. Owner: Risk management. Due: at each event.
Scope and timing
- Authority status
- Other (FDA early alert)
- Responsible owner
- Respiratory therapy, Supply chain, Clinical engineering, Critical care
- Publication date
- 2026-11-10
- Other dates
- 2026-11-03 Intersurgical letter to affected customers; injury status as of 2026-11-03
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →